AHA 2020

PHARMACOLOGY

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation discharged after successful...

solaci - 26 November, 2020

Chronic Ischemic cardiopathy

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI...

solaci - 25 November, 2020

Other

AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation

Results confirm the interim analysis, whereby the study was suspended for futility. Omega-3 fatty acids do not...

solaci - 24 November, 2020

Other

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure

Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and...

solaci - 23 November, 2020

Antithrombotic Anticoagulants

AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve

Rivaroxaban seems to be a reasonable alternative to warfarin in patients with atrial fibrillation and bioprosthetic mitral...

solaci - 20 November, 2020

Antiplatelet

AHA 2020 | Clopidogrel Resists as the Best Option in Elective Patients

High risk patients undergoing elective PCI treated with a more potent antiplatelet scheme (ticagrelor) vs. the classic...

solaci - 20 November, 2020

Acute coronary syndromes

AHA 2020 | In Most Cases, Imaging Can Determine What Causes MINOCA

Intravascular imaging with coronary optical coherence tomography (OCT) and magnetic resonance imaging allow for the identification of...

solaci - 20 November, 2020

Chronic Ischemic cardiopathy

AHA 2020 | The More Operators “Listen” to FFR, the Lower the Risk

When operators decide to proceed with PCI despite a negative FFR (fairly frequent in the daily practice)...

solaci - 20 November, 2020

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure

AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve

AHA 2020 | Clopidogrel Resists as the Best Option in Elective Patients

AHA 2020 | In Most Cases, Imaging Can Determine What Causes MINOCA

AHA 2020 | The More Operators “Listen” to FFR, the Lower the Risk

Últimas Noticias

Long Term Results of the International Chimney Registry

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

Noticias Institucionales

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

Check out the best images of the El Salvador 2024 Sessions

The El Salvador 2024 Sessions are coming soon

Accesos